See today's BioWorld Asia
To read the full story, subscribe or sign in.

Telix launches AU$650M bond offer, FDA accepts imaging NDA

July 30, 2024
By Tamra Sami
The U.S. FDA accepted Telix Pharmaceuticals Ltd.’s new drug application for TLX-007-CDx, a new cold kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer.
BioWorld Asia Financings Regulatory Cancer Oncology Imaging Asia-Pacific FDA